Evotec to realign Discovery Chemistry Operations
Evotec AG announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed at its Abingdon (UK) facility, answering to an increasing requirement to operate closer to the principal R&D laboratories of our major customers. All project work in Thane will be finished at the end of September and Evotec (India) Private Ltd will be wound down from then.
As a consequence 120 people will have to leave the company and Evotec will take a one-time impairment charge of up to EUR 4 m in Q3 2013.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Mutation Causes Heart Muscle Disorder - Researchers in Berlin und Boston Detect Genetic Defect
Research 'A' team to fast track Bionic Eye, Australian consortium announced

Long COVID: lower risk after an Omicron infection and after re-infection
Evotec and The Mark Foundation for Cancer Research announce strategic collaboration in immuno-oncology
Genomic 'firestorms' underlie aggressive breast cancer progression - Distinct genomic profiles useful for clinical diagnosis and therapy
New Phase II Data Shows Improvement in Disease Activity For Psioriasis Patients With Abbott's HUMIRA(R)
